AstraZeneca plc (AZN) Receives “Neutral” Rating from JPMorgan Chase & Co.

AstraZeneca plc (LON:AZN)‘s stock had its “neutral” rating reaffirmed by research analysts at JPMorgan Chase & Co. in a research report issued on Tuesday. They currently have a GBX 4,200 ($51.87) price target on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s target price would indicate a potential downside of 14.29% from the stock’s current price.

Several other equities analysts have also weighed in on AZN. Bryan, Garnier & Co restated a “buy” rating and set a GBX 5,100 ($62.99) price objective on shares of AstraZeneca plc in a research report on Tuesday, November 22nd. HSBC Holdings plc restated a “hold” rating and set a GBX 4,700 ($58.05) price objective on shares of AstraZeneca plc in a research report on Wednesday, November 23rd. Deutsche Bank AG restated a “buy” rating and set a GBX 6,000 ($74.10) price objective on shares of AstraZeneca plc in a research report on Wednesday, November 30th. Berenberg Bank restated a “buy” rating and set a GBX 5,500 ($67.93) price objective on shares of AstraZeneca plc in a research report on Tuesday, December 6th. Finally, Liberum Capital restated a “hold” rating and set a GBX 5,200 ($64.22) price objective on shares of AstraZeneca plc in a research report on Thursday, December 8th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. AstraZeneca plc has an average rating of “Hold” and an average target price of GBX 5,018.36 ($61.98).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

AstraZeneca plc (LON:AZN) opened at 4900.00 on Tuesday. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The firm’s 50-day moving average is GBX 4,617.49 and its 200-day moving average is GBX 4,602.58. The firm’s market cap is GBX 62.00 billion.

The firm also recently disclosed a dividend, which was paid on Monday, March 20th. Investors of record on Thursday, February 16th were given a dividend of GBX 150.20 ($1.86) per share. This represents a yield of 3.52%. The ex-dividend date of this dividend was Thursday, February 16th. This is a positive change from AstraZeneca plc’s previous dividend of $68.70.

Your IP Address:

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

McDonald’s Ordering Via Mobile Could Give Handsome Return
McDonald’s Ordering Via Mobile Could Give Handsome Return
Mattel CEO Promises Growth Following Sales Slump
Mattel CEO Promises Growth Following Sales Slump
Burberry Misses Estimates on Sales
Burberry Misses Estimates on Sales
Snapchat: CEO Did Not Label India as Being Poor
Snapchat: CEO Did Not Label India as Being Poor
Credit Suisse Slashes Bonuses by 40%
Credit Suisse Slashes Bonuses by 40%
Daily Mail to Pay Melania Trump $3 Million
Daily Mail to Pay Melania Trump $3 Million


© 2006-2017 Ticker Report. Google+.